menu search

cervical dysplasia treatment market to achieve us$ 846.2 million valuation by 2033 | future market insights inc.

Innovative cervical dysplasia treatments drive market growth, backed by government programs & patient d...

October 9, 2023, 12:30 am

Merck (mrk) keytruda cervical cancer sbla gets fda priority tag

The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of ...

September 21, 2023, 9:46 am

Ispecimen expands provider network to enhance support for women’s health research

Additional Providers Increase Biospecimen Access for Researchers Focused on cervical, Uterine and Breas...

September 13, 2023, 11:30 am

Zai lab adr surges after seagen, genmab release cervical cancer treatment results

Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% an...

September 5, 2023, 8:12 am

Sabin vaccine institute leads public and private sector fight to prevent hpv and end cervical cancer with global hpv consortium launch in kuala lumpur

KUALA LUMPUR, Malaysia, Sept. 05, 2023 (GLOBE NEWSWIRE) — The Global HPV Consortium, a worldwide public and private collaboration focused on acceler...

September 4, 2023, 10:00 pm

Genmab, seagen say tivdak cervical cancer trial met overall survival endpoint

Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervi...

September 4, 2023, 5:33 pm

Global cervical dysplasia treatment market size to achieve usd 1,063.67 million by 2030, grow at 7.10% cagr

[214 + Pages Report] According to a market research study published by Zion Market Research, the demand analysis of Global ...

August 21, 2023, 7:00 pm

Revance shares gain 8% after fda approval of cervical dystonia treatment

Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech compan...

August 14, 2023, 8:53 am

Femasys’ femcerv endocervical tissue sampler for cervical cancer diagnosis receives product approval in canada

– FemCerv® is the first endocervical tissue sampler designed to collect and contain a comprehensive ...

May 3, 2023, 12:30 pm

Celcuity to present preclinical data on therapeutic effects of gedatolisib in gynecological cancer models at aacr annual meeting 2023

MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted...

March 15, 2023, 7:35 pm

Bd's (bdx) new fda approval to improve cervical cancer testing

BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical...

February 27, 2023, 12:03 pm

Biovaxys technology finalizes us distribution deal with procare health iberia for papilocare gel and oral immunocaps

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) told investors it has now finalized and executed the previously announced US distribution agreement ...

December 19, 2022, 7:54 am

Regeneron's (regn) libtayo gets ec nod for cervical cancer

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic...

November 23, 2022, 12:03 pm

Glaxosmithkline's cervical cancer drug wins chinese approval

GlaxoSmithKline PLC (LSE:GSK)'s cervical cancer drug has been approved as a two-dose vaccine as protect...

May 27, 2022, 3:49 am

Biovaxys files to expand international cervical cancer vaccine patent protection

BioVaxys Technology Corp has moved to expand patent coverage for its cancer vaccine platform by filing an international patent application through the...

May 2, 2022, 12:29 pm

Dalrada hails second screening study in india of its cervia kit to test for cervical cancer

Dalrada Corporation (OTCQB:DFCO) has reported on the positive results of a second screening study of its patent-pending cerVIA kit used to test for ...

April 25, 2022, 9:17 am

Astrazeneca's (azn) imfinzi misses goal in cervical cancer study

AstraZeneca's (AZN) blockbuster drug Imfinzi fails to achieve progression-free survival endpoint with statistical significance in ...

March 25, 2022, 3:48 pm

Astrazeneca's imfinzi fails to meet primary endpoint in phase 3 cervical cancer trial

AstraZeneca PLC (LSE:AZN) said an advanced-stage study of its Imfinzi drug failed to meets its target of improving survival in patients with ...

March 24, 2022, 5:23 am

Regeneron, sanofi withdraw fda application for libtayo's expanded use

Regeneron Pharmaceuticals Inc  REGN and its partner Sanofi SA SNY have voluntarily withdrawn their application with the FDA for the expanded use ...

January 28, 2022, 10:31 am

Regeneron, sanofi withdraw fda application for libtayo's expanded use

Regeneron Pharmaceuticals Inc  REGN and its partner Sanofi SA SNY have voluntarily withdrawn their application with the FDA for the expanded use ...

January 28, 2022, 10:31 am


Search within

Pages Search Results: